FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a quinoline derivative of formula (1) or to one of its pharmaceutically acceptable salts, selected from hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, trichlorate, maleate, mesylate, formate, acetate and fumarate. Invention also relates to a pharmaceutical composition, a medicinal agent, a method of producing a compound of formula (4).
EFFECT: technical result is obtaining a novel quinoline derivative of formula (1), which can be used for treating or preventing HIV infection or HIV-related condition.
10 cl, 6 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
| MICRORNA-124 AS BIOMARKER | 2014 |
|
RU2687366C2 |
| METHOD OF INHIBITING HIV REPLICATION IN CELLS OF MAMMALS AND HUMANS | 2011 |
|
RU2593948C2 |
| LYSINE-RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | 2007 |
|
RU2458916C2 |
| METHOD FOR DETERMINING OPTIMUM CHEMOTHERAPY FOR TREATING HIV-SEROPOSITIVE PATIENTS BASED ON PHENOTYPIC HUMAN HIV STRAINS SENSITIVITY TO DRUGS | 1997 |
|
RU2174014C2 |
| COMPOSITION FOR PREVENTING AND/OR TREATING INFECTION, CAUSED BY HIV-1 | 2012 |
|
RU2603262C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HIV DISEASE IN HUMANS | 2012 |
|
RU2609769C2 |
| INGENOL DERIVATIVES FOR REACTIVATION OF LATENT HIV VIRUS | 2013 |
|
RU2609512C2 |
| MEDICINAL AGENT FOR TREATING INFECTIOUS DISEASES | 2014 |
|
RU2579262C1 |
| CYCLOBUTYL (S)-2-[[[R)-2-(6-AMINOPURIN-9-YL)-1-METHYL-ETOXY]METHYL-PHENOXY-PHOSPHORYL]AMINO]-PROPANOATES, METHOD OF THEIR PRODUCTION AND APPLICATION | 2017 |
|
RU2647576C1 |
